^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SH2B3 mutation

    i
    Other names: SH2B3, SH2B Adaptor Protein 3, Lymphocyte-Specific Adapter Protein Lnk, Signal Transduction Protein Lnk, SH2B Adapter Protein 3, LNK, Lymphocyte Adapter Protein, Lymphocyte Adaptor Protein, IDDM20
    Entrez ID:
    10019
    Related biomarkers:
    Mutation
    CNA
    Associations

    News

    Trials
    21d
    Myeloproliferative neoplasm with a homozygous germline SH2B3 mutation: a case report and literature review (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    As a negative regulator of JAK2, inactivating mutations in the SH2B3 gene lead to weakened negative regulation of the JAK2/STAT signaling pathway by the SH2B3 protein, thereby causing continuous activation of this pathway and inducing the development of MPN. After treatment with the JAK1/JAK2 inhibitor ruxolitinib 20 mg twice daily, the patient's body temperature returned to normal, fatigue and night sweats resolved, and spleen size decreased, demonstrating significant therapeutic efficacy.
    Retrospective data • Review • Journal
    |
    SH2B3 (SH2B Adaptor Protein 3)
    |
    SH2B3 mutation
    |
    Jakafi (ruxolitinib)
    4ms
    FT400-004: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (clinicaltrials.gov)
    P1, N=10, Completed, Zhejiang University | Recruiting --> Completed | N=16 --> 10 | Trial completion date: Aug 2025 --> May 2025 | Trial primary completion date: Aug 2025 --> May 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TCF3 (Transcription Factor 3) • SH2B3 (SH2B Adaptor Protein 3)
    |
    SH2B3 mutation
    7ms
    Long-term Follow-up of Gastrointestinal CAR T-cell Lymphoma: Homing, Clonal Expansion, and Response to Cyclosporine. (PubMed, Blood)
    We found clinical, histological, and molecular evidence demonstrating the efficacy of cyclosporine in reducing the expanded malignant clone and achieving durable clinical remission for more than a year. Our findings highlight the complex interplay between CAR T-cell therapy, pre-existing genetic vulnerabilities, and the GI microenvironment, emphasizing the need for vigilant monitoring and tailored therapeutic strategies to address the risks associated with CAR-T lymphomagenesis.
    Journal • IO biomarker
    |
    SH2B3 (SH2B Adaptor Protein 3) • TFCP2 (Transcription Factor CP2)
    |
    SH2B3 mutation
    |
    cyclosporine
    1year
    FT400-004: Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL (clinicaltrials.gov)
    P1, N=16, Recruiting, Zhejiang University | Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • FGFR (Fibroblast Growth Factor Receptor) • JAK2 (Janus kinase 2) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • IKZF1 (IKAROS Family Zinc Finger 1) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • TCF3 (Transcription Factor 3) • SH2B3 (SH2B Adaptor Protein 3)
    |
    SH2B3 mutation